Skip to content 
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina. more
| Time Frame | IRD | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 20.93% | -1.08% | -1.38% |
| 1-Month Return | 70.09% | -0.47% | -1.81% |
| 3-Month Return | 96.76% | 2.13% | 1.38% |
| 6-Month Return | 230.91% | 17.04% | 5.68% |
| 1-Year Return | 216.52% | 6.56% | 11.74% |
| 3-Year Return | -3.45% | 16.78% | 65.15% |
| 5-Year Return | -68.76% | 34.34% | 73.68% |
| 10-Year Return | -97.93% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | 589.00K | 39.85M | 19.05M | 10.99M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.8,"profit":true},{"date":"2024-12-31","value":27.58,"profit":true}] |
| Cost of Revenue | 8.00K | 4.00K | 4.00K | 6.00K | 10.00K | [{"date":"2020-12-31","value":80,"profit":true},{"date":"2021-12-31","value":40,"profit":true},{"date":"2022-12-31","value":40,"profit":true},{"date":"2023-12-31","value":60,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Profit | (8.00K) | 589.00K | 39.85M | 19.05M | 10.99M | [{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":1.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.8,"profit":true},{"date":"2024-12-31","value":27.58,"profit":true}] |
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 19.97M | 23.29M | 21.62M | 29.61M | 73.07M | [{"date":"2020-12-31","value":27.33,"profit":true},{"date":"2021-12-31","value":31.88,"profit":true},{"date":"2022-12-31","value":29.6,"profit":true},{"date":"2023-12-31","value":40.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (19.97M) | (22.70M) | 18.23M | (10.56M) | (62.07M) | [{"date":"2020-12-31","value":-109.56,"profit":false},{"date":"2021-12-31","value":-124.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-57.96,"profit":false},{"date":"2024-12-31","value":-340.58,"profit":false}] |
| Total Non-Operating Income/Expense | (11.50M) | (33.99M) | (32.00K) | (739.00K) | 4.54M | [{"date":"2020-12-31","value":-253.17,"profit":false},{"date":"2021-12-31","value":-748.35,"profit":false},{"date":"2022-12-31","value":-0.7,"profit":false},{"date":"2023-12-31","value":-16.27,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (24.62M) | (56.69M) | 18.20M | (9.97M) | (57.53M) | [{"date":"2020-12-31","value":-135.25,"profit":false},{"date":"2021-12-31","value":-311.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-54.79,"profit":false},{"date":"2024-12-31","value":-316.06,"profit":false}] |
| Income Taxes | - | - | 315.00K | 12.00K | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":3.81,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | 17.89M | (9.99M) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (24.62M) | (56.69M) | 17.89M | (9.99M) | (57.53M) | [{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false},{"date":"2024-12-31","value":-321.62,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (24.62M) | (56.69M) | 17.89M | (9.99M) | (57.53M) | [{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false},{"date":"2024-12-31","value":-321.62,"profit":false}] |
| EPS (Diluted) | (8.11) | (4.69) | 0.76 | (0.48) | (2.15) | [{"date":"2020-12-31","value":-1067.11,"profit":false},{"date":"2021-12-31","value":-617.11,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-63.16,"profit":false},{"date":"2024-12-31","value":-282.62,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| IRD | |
|---|---|
| Cash Ratio | 1.06 |
| Current Ratio | 1.23 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| IRD | |
|---|---|
| ROA (LTM) | -60.74% |
| ROE (LTM) | -338.75% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| IRD | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.83 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| IRD | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 15.98 |
| P/B | 39.30 |
| Price/FCF | NM |
| EV/R | 13.99 |
| EV/Ebitda | NM |
Opus Genetics, Inc. (IRD) share price today is $3.64
Yes, Indians can buy shares of Opus Genetics, Inc. (IRD) on Vested. To buy
Yes, you can purchase fractional shares of Opus Genetics, Inc. (IRD) via the Vested app. You can start investing in Opus Genetics, Inc. (IRD) with a minimum investment of $1.
You can invest in shares of Opus Genetics, Inc. (IRD) via Vested in three simple steps:
The 52-week high price of Opus Genetics, Inc. (IRD) is $3.57. The 52-week low price of Opus Genetics, Inc. (IRD) is $0.65.
The price-to-earnings (P/E) ratio of Opus Genetics, Inc. (IRD) is
The price-to-book (P/B) ratio of Opus Genetics, Inc. (IRD) is 39.30
The dividend yield of Opus Genetics, Inc. (IRD) is 0.00%
The market capitalization of Opus Genetics, Inc. (IRD) is $233.79M
The stock symbol (or ticker) of Opus Genetics, Inc. is IRD
Consider the share price of Opus Genetics, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Opus Genetics, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Opus Genetics, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Opus Genetics, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Opus Genetics, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Opus Genetics, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
